2017 City of Hope Hematologic Malignancies Symposium


Blinatumomab ‘Takes a BiTE’ Out of Acute Lymphoblastic Leukemia

An investigational immunotherapy is improving outcomes in difficult-to-treat acute lymphoblastic leukemia (ALL) and showing promise in other cancers, as well. Blinatumomab (Blincyto), the first U.S. F...

Multiple Myeloma

Immune System Is Shaping the Future of Multiple Myeloma Treatment

From immunomodulatory agents and proteasome inhibitors to steroids, alkylators, and antibodies, recent years have witnessed an explosion of drug approvals for multiple myeloma. The challenge now, sai...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.